MOR107: Ph I started

MorphoSys said its Lanthio Pharma B.V. subsidiary began a double-blind, placebo-controlled, U.K. Phase I trial to evaluate single ascending doses of subcutaneous MOR107 in 80-110 healthy male voluntee...